06.08.2010 TEMPO study further demonstrates
the benefits of Azilect® in early Parkinson's
disease patients |
|
H.Lundbeck
A/S
and
Teva
Pharmaceutical Industries Ltd.
(NASDAQ:
TEVA) today announced newly published
long-term data on Azilect® (rasagiline
tablets) from the TEMPO study and its
open-label extension. The findings confirm
the long-term efficacy, safety and
tolerability of Azilect® in patients with
Parkinson's disease (PD) and further
demonstrate the benefits obtained with early
treatment initiation. The data was published
in the June 2010 issue of the International
Journal of Neuroscience.
 |
 |
|
|
|
|
21.07.2010 Phillips and Dako join
forces in Digital Pathology |
|
Royal Philips Electronics
(NYSE: PHG, AEX: PHI) and
Dako,
a Danish company specializing in tissue-based cancer
diagnostics, today announced that they have signed an
agreement to integrate a selection of Dako’s image
analysis applications into Philips’ future digital
pathology solutions.
|
 |
|
|
|
|
27.05.2010 First patients recruited
in the extended phase III programme using Lu AA21004 in MDD |
|
H.Lundbeck
A/S
today announced that the first
patients have been recruited and dosed in the new phase III
programme using Lu AA21004 in major depression (MDD). The first
patients have been recruited in Finland.
|
|
|
|
|
|
25.05.2010 Lundbeck
will submit an NDA for clobazam for patients with
Lennox-Gastaut syndrome with the FDA before year end
2010 |
|
In March 2009,
H.Lundbeck
A/S
acquired Ovation Pharmaceuticals, Inc. (now
Lundbeck Inc.). As part of the acquisition Lundbeck obtained the
rights for clobazam in the US, a product in development for patients
with Lennox-Gastaut syndrome (LGS). Lundbeck expects clobazam to be
able to provide additional growth opportunities for the US operation
as well as for the whole group.
|
|
|
|
|
|
17.05.2010 Positive
pivotal results on escitalopram in Japan -
Lundbeck's partner Mochida plans to file
escitalopram for regulatory approval in first
quarter 2011 at the latest |
|
H.Lundbeck
A/S
today announced that
the results from the pivotal study with
escitalopram in Japan have been received.
The results are positive and according to
expectations.
In April 2008 Mochida Pharmaceutical Co.,
Ltd. (Mochida) initiated the clinical phase III placebo-co with MDD
were randomised to receive
escitalopram (10 or 20mg), paroxetine
ontrolled study in major depression (MDD). Approximately 480
patientsr
placebo.
|
|
|
|
|
|
16.04.2010 Update on legal
proceedings |
|
H.Lundbeck
A/S
(Lundbeck)
has been informed of
a favorable ruling from the City Court in Elsinore in a preliminary
injunction case in Denmark. The decision means that generic versions
of escitalopram in Denmark have to be removed from the market. The
decision can be appealed by the other side.
|
|
|
|
|
07.04.2010 Desmoteplase enters clinical
phase II in Japan in ischaemic stroke representing Lundbecks first
clinical programme in Japan |
H.Lundbeck
A/S
(Lundbeck)
strengthens its pipeline of pharmaceuticals
in clinical development by initiating phase
I clinical studies with Lu AE04621 in order
to investigate safety, tolerability and the
pharmacokinetic profile of the drug in
humans. The placebo-controlled study is
expected to enrol around 100 healthy
individuals.
|
|
| |
|
| |
|
| |
|
| |
|
All rights reserved